Patrick Holder

Title: Innovator Patrick Holder: Advancements in Cancer Treatment

Introduction

Patrick Holder, an innovator based in South San Francisco, California, has significantly contributed to the field of biotechnology with his pioneering work. Notably, he is recognized for his research and development in cancer treatment through novel fusion proteins.

Latest Patents

Holder holds a patent for "PD-1 targeted IL-15/IL-15Rα Fc fusion proteins with improved properties." This innovative invention focuses on fusion proteins that incorporate variant IL-15 proteins and anti-PD-1 antigen binding domains. The patent addresses the creation of nucleic acid molecules, expression vectors, and host cells, outlining methods for producing these fusion proteins. Furthermore, it explores the therapeutic applications of these proteins in cancer treatment, highlighting their potential in advancing patient care.

Career Highlights

Patrick Holder has had an impressive career, having worked with prominent companies in the biotechnology industry, including Genentech, Inc. and Xencor, Inc. These roles have allowed him to collaborate with leading experts and contribute to groundbreaking therapeutic developments.

Collaborations

Throughout his career, Holder has collaborated with notable professionals in his field, including John R. Desjarlais and Matthew J. Bernett. These partnerships have enhanced his research and have been instrumental in the successful development of his patented innovations.

Conclusion

Patrick Holder's innovative contributions in the realm of cancer treatment through his patented fusion proteins exemplify the impact of biotechnology on healthcare. His collaborations and experiences at leading companies position him as a significant figure in the ongoing fight against cancer, paving the way for future advancements in the field.